Acute Myeloid Leukaemia - FOI Response Register

1. Do you treat patients with acute myeloid leukaemia (AML) in your Trust?

Yes

If yes, please proceed to Question 3, if no, please answer Question 2

2. Where do patients diagnosed with AML in your Trust receive treatment?

Shared care between NHS Grampian and NHS Shetland as some treatments cannot be delivered locally, due to regime or drug expiry.

3. Please complete the table below with how many newly diagnosed patients with AML have started first-line treatment with each of the following therapies during the 6-month period October 2023 to March 2024?

• Azacitidine monotherapy
• Low dose cytarabine (LoDAC) monotherapy
• Venetoclax + azacitidine
• Venetoclax + LoDAC
• Ivosidenib
• Intensive chemotherapy-based regimen

Examples include: cytarabine and daunorubicin, idarubicin, fludarabine, mitoxantrone, etoposide (VP-16), 6-thioguanine (6-TG), methotrexate (MTX) or 6-mercaptopurine (6-MP), gemtuzumab ozogamicin with daunorubicin cytarabine, or FLAG-Ida (fludarabine, cytarabine, granulocyte-colony stimulating factor and idarubicin)

• Best supportive care
• Other

Do not include prophylactic therapies such as GCSF, anti-fungals, antihistamines, anti-nauseants

Note: this should only include patients with AML who have started first-line treatment during the 6-month window

The request covers a short time frame, a specific condition and specific treatment information. Given the high risk of identifying individuals and the sensitivity of the requested information, NHS Shetland is unable to provide the requested information. As such and in accordance with FOISA s 16(1), NHS Shetland confirms that it holds the information requested but that it is exempt from disclosure under FOISA s 38(1)(b) as read with s 38 (2A) as the information constitutes personal data and disclosure would breach the confidentiality of the data subject(s).